Immunome, Inc.
IMNM
$27.20
$0.782.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | -- | 4.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | -- | 4.02M |
| Cost of Revenue | 59.89M | 46.38M | 50.77M | 49.19M | 40.45M |
| Gross Profit | -59.89M | -46.38M | -50.77M | -49.19M | -36.44M |
| SG&A Expenses | 18.25M | 12.95M | 12.09M | 10.95M | 10.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.14M | 59.33M | 62.86M | 60.14M | 50.49M |
| Operating Income | -78.14M | -59.33M | -62.86M | -60.14M | -46.48M |
| Income Before Tax | -73.13M | -53.84M | -69.90M | -57.46M | -43.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.13M | -53.84M | -69.90M | -57.46M | -43.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.13M | -53.84M | -69.90M | -57.46M | -43.40M |
| EBIT | -78.14M | -59.33M | -62.86M | -60.14M | -46.48M |
| EBITDA | -77.18M | -58.73M | -62.23M | -59.55M | -45.84M |
| EPS Basic | -0.65 | -0.48 | -0.74 | -0.65 | -0.50 |
| Normalized Basic EPS | -0.40 | -0.30 | -0.39 | -0.41 | -0.31 |
| EPS Diluted | -0.65 | -0.48 | -0.74 | -0.65 | -0.50 |
| Normalized Diluted EPS | -0.40 | -0.30 | -0.39 | -0.41 | -0.31 |
| Average Basic Shares Outstanding | 113.27M | 113.14M | 94.93M | 87.96M | 87.01M |
| Average Diluted Shares Outstanding | 113.27M | 113.14M | 94.93M | 87.96M | 87.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |